Recent News About AbbVie
By Business Daily | Mar 26, 2025
AbbVie has announced that it will present new data from its early oncology research at the American Association of Cancer Research (AACR) Annual Meeting, scheduled for April 25-30, 2025.
By Business Daily | Mar 24, 2025
Allergan Aesthetics, a subsidiary of AbbVie, is showcasing its latest innovations at the Anti-Aging and Aesthetics Medicine World Congress (AMWC) in Monaco from March 27 to March 29, 2025.
By Business Daily | Mar 15, 2025
AbbVie has released the final data from its Phase 3 MIRASOL trial, demonstrating a notable survival benefit for ELAHERE (mirvetuximab soravtansine-gynx) in patients with folate receptor alpha-positive platinum-resistant ovarian cancer.
By Business Daily | Mar 4, 2025
AbbVie has announced its participation in the upcoming Leerink Partners Global Healthcare Conference.
By Business Daily | Mar 3, 2025
AbbVie and Gubra have announced a license agreement to develop an amylin analog, GUB014295, for obesity treatment.
By A. I. Benavidez | Feb 26, 2025
AbbVie is set to participate in the TD Cowen's 45th Annual Health Care Conference, scheduled for Wednesday, March 5, 2025.
By A. A. Sanchez | Feb 14, 2025
AbbVie has announced that its board of directors unanimously elected CEO Robert A. Michael to also serve as chairman, effective July 1, 2025.
By A. A. Sanchez | Feb 13, 2025
The board of directors at AbbVie Inc. has announced a quarterly cash dividend of $1.64 per share.
By A. A. Sanchez | Feb 12, 2025
AbbVie and Xilio Therapeutics have entered into a collaboration and option-to-license agreement to develop novel tumor-activated, antibody-based immunotherapies.
By A. A. Sanchez | Feb 12, 2025
Allergan Aesthetics, a company under AbbVie, is set to open three new Allergan Medical Institute (AMI) Training Centers in the United States.
By K. R. Nelson | Feb 7, 2025
The U.S. Food and Drug Administration (FDA) has approved EMBLAVEO, a combination of aztreonam and avibactam, for treating adults with complicated intra-abdominal infections (cIAI).
